Loading...

Katsunobu Hagihara, PhD

TitlePostdoctoral Scholar
SchoolUCSF School of Medicine
DepartmentMedicine
Address513 Parnassus Ave, Med Sci
San Francisco CA 94122
Phone415-514-9301
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul; 107(7):1039-46. PMID: 27166974.
      View in: PubMed
    2. Ohtoyo M, Machinaga N, Inoue R, Hagihara K, Yuita H, Tamura M, Hashimoto R, Chiba J, Muro F, Watanabe J, Kobayashi Y, Abe K, Kita Y, Nagasaki M, Shimozato T. Component of Caramel Food Coloring, THI, Causes Lymphopenia Indirectly via a Key Metabolic Intermediate. Cell Chem Biol. 2016 May 19; 23(5):555-60. PMID: 27185637.
      View in: PubMed
    3. Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N, Soma M, Okamoto H, Oitate M, Arakawa S, Hirai T, Atsumi R, Nakada T, Hayakawa I, Abe Y, Agatsuma T. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. Clin Cancer Res. 2016 Oct 15; 22(20):5097-5108. PMID: 27026201.
      View in: PubMed
    4. Kazui M, Ogura Y, Hagihara K, Kubota K, Kurihara A. Human Intestinal Raf Kinase Inhibitor Protein (RKIP) Catalyzes Prasugrel as a Bioactivation Hydrolase. Drug Metab Dispos. 2016 Jan; 44(1):115-23. PMID: 26558823.
      View in: PubMed
    5. Hirasawa M, Hagihara K, Okudaira N, Izumi T. The Possible Mechanism of Idiosyncratic Lapatinib-Induced Liver Injury in Patients Carrying Human Leukocyte Antigen-DRB1*07:01. PLoS One. 2015; 10(6):e0130928. PMID: 26098642; PMCID: PMC4476721.
    6. Kazui M, Hagihara K, Izumi T, Ikeda T, Kurihara A. Hepatic microsomal thiol methyltransferase is involved in stereoselective methylation of pharmacologically active metabolite of prasugrel. Drug Metab Dispos. 2014 Jul; 42(7):1138-45. PMID: 24733788.
      View in: PubMed
    7. Hagihara K, Kazui M, Kurihara A, Ikeda T, Izumi T. Glutaredoxin is involved in the formation of the pharmacologically active metabolite of clopidogrel from its GSH conjugate. Drug Metab Dispos. 2012 Sep; 40(9):1854-9. PMID: 22733806.
      View in: PubMed
    8. Hagihara K, Kazui M, Ikenaga H, Nanba T, Fusegawa K, Izumi T, Ikeda T, Kurihara A. The intestine as an important contributor to prasugrel active metabolite formation in vivo. Drug Metab Dispos. 2011 Apr; 39(4):565-70. PMID: 21189331.
      View in: PubMed
    9. Hagihara K, Kazui M, Kurihara A, Kubota K, Ikeda T. Glutaredoxin and thioredoxin can be involved in producing the pharmacologically active metabolite of a thienopyridine antiplatelet agent, prasugrel. Drug Metab Dispos. 2011 Feb; 39(2):208-14. PMID: 21036950.
      View in: PubMed
    10. Hagihara K, Kazui M, Kurihara A, Iwabuchi H, Ishikawa M, Kobayashi H, Tanaka N, Okazaki O, Farid NA, Ikeda T. Biotransformation of prasugrel, a novel thienopyridine antiplatelet agent, to the pharmacologically active metabolite. Drug Metab Dispos. 2010 Jun; 38(6):898-904. PMID: 20228231.
      View in: PubMed
    11. Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, Ikeda T, Kurihara A. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos. 2010 Jan; 38(1):92-9. PMID: 19812348.
      View in: PubMed
    12. Hagihara K, Kazui M, Kurihara A, Yoshiike M, Honda K, Okazaki O, Farid NA, Ikeda T. A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. Drug Metab Dispos. 2009 Nov; 37(11):2145-52. PMID: 19704027.
      View in: PubMed
    13. Nishiya Y, Hagihara K, Ito T, Tajima M, Miura S, Kurihara A, Farid NA, Ikeda T. Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel. Drug Metab Dispos. 2009 Mar; 37(3):589-93. PMID: 19047469.
      View in: PubMed
    14. Hagihara K, Nishiya Y, Kurihara A, Kazui M, Farid NA, Ikeda T. Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine. Drug Metab Pharmacokinet. 2008; 23(6):412-20. PMID: 19122335.
      View in: PubMed
    15. Kohama Y, Shinoda S, Hagihara K, Hashimoto T, Yamaguchi A, Nakamura A, Tsuchiya T, Tsujikawa K, Yamamoto H. Isolation of proliferation factor of immature T-cell clone in concanavalin A-stimulated splenocyte culture supernatant. Immunology. 2003 Jun; 109(2):209-16. PMID: 12757615; PMCID: PMC1782958.
    Katsunobu's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Related Authors
    People who share related concepts with this person.
    _
    Back to TOP